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Abstract
Background/aims: In clinical trials, it is not unusual for errors to occur during the process of recruiting, randomising and pro-
viding treatment to participants. For example, an ineligible participant may inadvertently be randomised, a participant may be ran-
domised in the incorrect stratum, a participant may be randomised multiple times when only a single randomisation is permitted
or the incorrect treatment may inadvertently be issued to a participant at randomisation. Such errors have the potential to intro-
duce bias into treatment effect estimates and affect the validity of the trial, yet there is little motivation for researchers to report
these errors and it is unclear how often they occur. The aim of this study is to assess the prevalence of recruitment, randomisa-
tion and treatment errors and review current approaches for reporting these errors in trials published in leading medical journals.
Methods: We conducted a systematic review of individually randomised, phase III, randomised controlled trials published in
New England Journal of Medicine, Lancet, Journal of the American Medical Association, and Annals of Internal Medicine and British
Medical Journal from January to March 2015. The number and type of recruitment, randomisation and treatment errors that
were reported and how they were handled were recorded. The corresponding authors were contacted for a random sample
of trials included in the review and asked to provide details on unreported errors that occurred during their trial.
Results: We identified 241 potentially eligible articles, of which 82 met the inclusion criteria and were included in the
review. These trials involved a median of 24 centres and 650 participants, and 87% involved two treatment arms.
Recruitment, randomisation or treatment errors were reported in 32 in 82 trials (39%) that had a median of eight
errors. The most commonly reported error was ineligible participants inadvertently being randomised. No mention of
recruitment, randomisation or treatment errors was found in the remaining 50 of 82 trials (61%). Based on responses
from 9 of the 15 corresponding authors who were contacted regarding recruitment, randomisation and treatment
errors, between 1% and 100% of the errors that occurred in their trials were reported in the trial publications.
Conclusion: Recruitment, randomisation and treatment errors are common in individually randomised, phase III trials
published in leading medical journals, but reporting practices are inadequate and reporting standards are needed. We
recommend researchers report all such errors that occurred during the trial and describe how they were handled in
trial publications to improve transparency in reporting of clinical trials.
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Introduction
Randomisation is the unique and most critical feature
of randomised controlled trials (RCTs), enabling the
formation of similar treatment groups at baseline and
an unbiased estimate of the treatment effect. In practice,
the randomisation process typically involves a series of
steps, from assessing eligibility and obtaining consent,
through to performing the randomisation and providing
the assigned treatment. Even in well-conducted trials, it
is not uncommon for errors to occur during this process
of recruiting, randomising and providing treatment to
participants. For example, an ineligible participant may
inadvertently be randomised, a participant may be ran-
domised in the incorrect stratum, a participant may be
randomised multiple times when only a single randomi-
sation is permitted or the incorrect treatment may inad-
vertently be issued to a participant at randomisation.
Such errors have the potential to undermine the benefits
of randomisation, affect the validity of the trial and
introduce bias into treatment effect estimates if handled
incorrectly, yet detailed discussion of these specific
errors in the literature remains limited.1,2
When recruitment, randomisation or treatment
errors occur, it is important to report their existence
and describe how they were handled in trial publica-
tions, as this allows readers to assess the extent of the
problem and whether the errors were dealt with appro-
priately. Guidance on handling common recruitment,
randomisation and treatment errors has been provided
previously.1,2 However, there is little motivation for
researchers to report these errors, as they are not a
requirement in the widely adopted Consolidated
Standards of Reporting Trials (CONSORT) state-
ment.3,4 It is unclear how often recruitment, randomi-
sation and treatment errors occur in trials and how
they are reported in trial publications. The aim of this
study is to assess the prevalence of recruitment, rando-
misation and treatment errors and review current
approaches for reporting these errors in individually
randomised, phase III RCTs published in leading
medical journals. We focus on the adequacy of report-
ing practices in relation to the errors, rather than the
adequacy of the trial conduct that may have enabled
such errors to occur.
Methods
A systematic review was conducted according to a pre-
specified protocol. The review was restricted to the five
leading medical journals according to their 2014 impact
factor (New England Journal of Medicine, Lancet,
Journal of the American Medical Association, Annals of
Internal Medicine, British Medical Journal), as report-
ing quality is expected to be high in these journals. All
journals publish one issue each week, except for Annals
of Internal Medicine which is published fortnightly. The
search was conducted in PubMed on 1 December 2015
using the search terms (Annals of internal medicine
(Journal) OR BMJ (Journal) OR Lancet (Journal) OR
JAMA (Journal) OR The New England journal of med-
icine (Journal)) AND (randomized controlled trial(pt)
OR controlled clinical trial(pt) OR randomized(tiab)
OR randomized(tiab) OR placebo(tiab) OR clinical
trials as topic (mesh: noexp) OR randomly(tiab) OR
trial(ti)) AND (2015/01/01 (PDat) : 2015/03/31 (PDat))
NOT (animals(mh) NOT humans(mh)). These search
terms are identical to those specified in the sensitivity
and precision-maximising version of the Cochrane
highly sensitive search strategy for identifying rando-
mised trials in MEDLINE (PubMed format)5 with sev-
eral additions. First, the search term ‘randomised[tiab]’
was added, as the Cochrane strategy only includes the
American spelling ‘randomized’ and some included
journals use the British spelling. Second, search terms
were added for the journals of interest and the 3-month
time period (January–March 2015) that was chosen
both for feasibility and to allow time for the articles to
be Medical Subject Heading indexed prior to conduct-
ing the search.
Articles were eligible for inclusion in the review if they
reported the results of an individually randomised, phase
III, RCT conducted in humans. Articles were excluded if
they indicated they reported the results of a pilot, feasibil-
ity, phase I, phase II or cluster randomised trial, as these
trials may substantively differ from individually rando-
mised, phase III trials in their conduct, protocol and data
monitoring procedures and may therefore have qualita-
tively different error rates. Short reports or articles pre-
senting the results of multiple trials together were also
excluded, as these have less space to provide details about
any errors that occurred. To ensure that each trial was
included only once in the review, only the first article
reporting the primary trial results was eligible.
Titles and abstracts of all articles identified in the
search were independently assessed for potential elig-
ibility by two reviewers (L.N.Y. and E.D.). The full text
of all potentially eligible articles was then examined by
L.N.Y., with a 20% random sample independently
examined by a second reviewer (B.C.K. or J.A.C.), to
confirm eligibility and extract trial details for eligible
trials using a purpose-specific data extraction form.
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The published articles and supplementary results files
were included in the review process but not the trial
protocols for feasibility. An initial version of the data
extraction form was piloted by two reviewers (L.N.Y.
and B.C.K.) on one article from each journal of interest
published in 2014. Final changes were made to the form
based on discussion prior to conducting the full text
review. Any disagreements between reviewers were
resolved by discussion.
For each eligible article, basic trial characteristics
were collected, including the number of participants,
centres and treatment arms, the methods used to gener-
ate the randomisation sequence and perform the rando-
misation and whether participants were allowed to be
randomised multiple times. In extracting details of the
recruitment, randomisation and treatment errors that
were reported, four specific types of errors that have
been discussed in detail previously2 were assessed: ineli-
gible participant randomised, participant randomised
using incorrect baseline information (e.g. participant
randomised in incorrect stratum), participant incor-
rectly randomised multiple times and participant
received incorrect treatment. For the latter error, all
instances of participants receiving the incorrect treat-
ment were documented. Further details were recorded,
where available, to enable the reviewer to determine
whether any instances were due to errors rather than
deliberate departures from the assigned treatment (non-
compliance), as we were only interested in identifying
errors. Free text fields were used to document any other
errors that occurred during the process of recruiting,
randomising and providing treatment to participants.
Details on each type of error were recorded, including
the number of errors that occurred, where the errors
were reported and any information provided on how
they were handled during the conduct of the trial or in
the analysis. The number and percentage of trials
reporting each type of error were calculated. The total
number and prevalence of reported errors were sum-
marised across trials by the median and range. Trials
that did not mention any errors were excluded from
these summaries, as it was unclear whether they had
zero errors or failed to report the errors that had
occurred. Prevalence was expressed as the number of
errors reported per 10,000 participants randomised,
since each participant provides an opportunity for an
error to occur and there was considerable variation in
sample size across trials.
As trial publications may not provide full details of
all recruitment, randomisation and treatment errors that
occurred, a random sample of corresponding authors
were contacted to seek clarification regarding these
errors for their trial. Specifically, we asked (a) whether
all errors that occurred in the trial were correctly identi-
fied by our review and (b) for details on the number and
type of errors not reported in the trial publication and
hence not identified by our review. Where no response
was received, a single follow-up email was sent several
weeks later. Only the random sample of trials selected
for duplicate review that were subsequently found to be
eligible were included in this process for feasibility. The
corresponding authors were advised that responses
would be presented in summary format only and not
associated with their individual trial.
Results
The search strategy identified 241 articles. Based on the
title and abstract review, both reviewers agreed on
whether the article should proceed to full text review or
not for 230 of 241 articles (95%). There were 89 articles
that underwent a full text review, of which 82 articles
(92%) met the inclusion criteria and were included in
the review (see Supplementary Material). There were
18 of 89 articles (20%) randomly selected for duplicate
full text review. Both reviewers agreed on whether the
article was eligible or not for 16 of 18 articles (89%),
and 15 of 18 articles (83%) met the inclusion criteria
and were included in the review (Figure 1).
The characteristics of the 82 trials included in the
review are presented in Table 1. The majority of trials
were published in either Lancet (39%) or New England
Journal of Medicine (37%). The trials varied greatly in
size, with a median of 24 centres and 650 participants.
Most trials involved two treatment arms (87%) and
had a publicly available protocol (77%). Many trials
failed to clearly describe the methods used to generate
the randomisation sequence (29%) or how the rando-
misation was performed (34%). Where randomisation
was clearly described, it was most commonly performed
using a web-based system (27%), and half the trials
used stratified permuted blocks to generate the rando-
misation sequence. Only 12 of 82 trials (15%) explicitly
stated that repeat randomisations were not permitted
as part of the inclusion/exclusion criteria.
One or more recruitment, randomisation or treat-
ment errors were reported in 32 of 82 trials (39%) that
had a median of eight errors reported (range 1–176)
and 906 randomised participants per trial. The number
of errors reported per 10,000 participants randomised
varied greatly across these 32 trials, ranging from 2 to
934 (median 71). For the remaining 50 of 82 trials
(61%) that included a median of 505 randomised parti-
cipants, we found no mention of any errors and were
unable to determine whether no errors had occurred or
errors had occurred but not been reported.
The specific types of errors reported are summarised
in Table 2. There were 23 of 82 trials (28%) reporting
that ineligible participants had been inadvertently ran-
domised, with a median of 12 ineligible participants
randomised per trial (range 1–80). This information
was typically reported in the results section or flow dia-
gram but could also be found in a table or online
Yelland et al. 3
supplement. While few trials explicitly stated how the
ineligible participants were handled, it was possible to
infer that they were excluded from the primary analysis
in 12 of 23 trials (52%), and included in the primary
analysis in 11 of 23 trials (48%), based on the flow dia-
gram and statistical methods section. Only 2 of 82 trials
(2%) reported that any participants were randomised
using incorrect baseline information, both of which
involved the use of stratified permuted blocks. In one
of these trials, four errors were reported in the flow dia-
gram and the affected participants were excluded from
the primary analysis. In the other trial, eight errors
were reported in the online supplementary material,
and the affected participants were included in the anal-
ysis, although it was unclear whether the correct or
incorrect baseline information was used in the adjusted
analysis. No trial reported that a participant was ran-
domised multiple times in error. Most of the 82 trials
included in the review (n = 64, 78%) reported that
one or more participants failed to receive the allocated
treatment (median seven participants per trial), and this
information was usually included in the flow diagram.
However, only 42% (27/64) of these trials provided suf-
ficient detail to determine whether any instances were
due to errors (n = 4 trials) or other reasons, such as
participant withdrawal, participant non-compliance or
treatment provider recommendation (n = 23 trials).
The number of participants who failed to receive the
allocated treatment in the four trials where it was
clearly due to an error ranged from two to eight, and in
each trial the affected participants were included in
their randomised groups in an intention-to-treat analy-
sis. There were 9 of 82 trials (11%) that reported other
types of errors, and these were typically identified from
the flow diagram or online supplement. The most com-
mon other type of error was failure to randomise peo-
ple who were eligible for the trial and had provided
consent to participate.
Of the 15 of 82 trials (18%) included in the review
where the corresponding authors were contacted
regarding errors for their trial, responses were received
from 9 of 15 trials (60%) that randomised a median of
640 participants. Between 1% and 100% of the errors
that had occurred in these trials were reported in the
trial publications. Two trials provided information on
an additional 301 errors that were not reported in the
trial publications: 286 ineligible participants were inad-
vertently randomised, 3 participants were randomised
following improper consent procedures, 4 participants
were possibly given the incorrect treatment at randomi-
sation, 6 participants were definitely given the incorrect
treatment at randomisation and 2 participants were
randomised twice in error. No additional errors were
reported for the remaining seven trials.
Discussion
Recruitment, randomisation and treatment errors were
common in individually randomised, phase III RCTs
published in leading medical journals in 2015, with
39% (32/82) of trials reporting at least one error. While
the number of errors reported was fairly small relative
Figure 1. Flow diagram.
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to the number of participants randomised (median 71
errors per 10,000 participants randomised), we believe
these errors are both common and important enough to
warrant careful consideration regarding how they might
be prevented, and how they should be handled during
the conduct of the trial and in the analysis when they
do occur. Recruitment errors may be reduced by use of
a dummy enrolment run-in phase.6 Randomisation
errors may be minimised by thoroughly checking the
randomisation sequence and testing the randomisation
system prior to commencing the trial.1 Methods for
handling common recruitment, randomisation and
treatment errors that maintain the goals of the
intention-to-treat principle have been discussed in detail
elsewhere.2 Such methods should ideally be pre-
specified in the trial protocol and this could be incorpo-
rated in a future SPIRIT statement.7,8
Estimating the true prevalence of recruitment, ran-
domisation and treatment errors based on errors
reported in trial publications is challenging. If the 61%
(50/82) of trials included in our review that did not
mention any errors in fact had no errors, then we have
overestimated the median number of errors per trial. In
contrast, if reporting of errors was incomplete, then we
may have underestimated the median. The latter sce-
nario is more likely, given our finding that as little as
1% of errors that occur in a trial may be reported. It is
difficult to estimate the true rate of under-reporting
based on this finding due to the small number of corre-
sponding authors contacted (15), the moderate
response rate (60%) and the possibility that this pro-
cess did not identify all unreported errors. Despite
these limitations, our survey of the corresponding
authors remains valuable as it confirms previous specu-
lation that errors occur more often than they are
reported1 and highlights the inadequacy of current
reporting practices. More accurate estimates of the pre-
valence of recruitment, randomisation and treatment
errors could be obtained from future trial publications
if reporting practices improve.
We are aware of one previous review that assessed
the prevalence and reporting of recruitment, randomi-
sation and treatment errors as part of a broader review
of protocol violations.9 Among 80 cluster or individu-
ally randomised trials published in leading medical
journals in 2009, 13% of trials reported ‘enrolment
protocol violations’, with a median of 0.8% of partici-
pants found to be ineligible (or 80 per 10,000 rando-
mised). This error was more common in our review,
where 28% of trials reported that a median of 91 parti-
cipants per 10,000 randomised were ineligible.
‘Randomisation protocol violations’ were reported in
9% of trials included in the previous review, while only
2% of trials in our review reported that participants
were randomised using incorrect baseline information.
‘Study intervention protocol violations’ were reported
in 21% of trials in the previous review, with a median
of 1.3% of participants (or 130 per 10,000 randomised)
experiencing ‘a dosing, timing or delivery error in the
study intervention attributable to members of the
research team’. Treatment errors were less common in
our review, where only 5% of trials reported errors
affecting a median of 41 participants per 10,000 rando-
mised. Differences in findings between the reviews may
reflect changes in reporting practices over time or dif-
ferences in the definitions and methodology used. Our
review adds to this study by considering any errors that
occurred during the process of recruiting, randomising
and providing treatment to participants, and providing
evidence of under-reporting of these errors by contact-
ing corresponding authors.
The potential for recruitment, randomisation and
treatment errors to impact on the trial results depends
Table 1. Characteristics of included trials.
Characteristic Summarya
(n = 82 trials)
Journal
Lancet 32 (39)
New England Journal of Medicine 30 (37)
Journal of the American Medical Association 10 (12)
Annals of Internal Medicine 5 (6)
British Medical Journal 5 (6)
Number of participants: median (range) 650 (40–84,496)
Number of centres: median (range)b 24 (1–1161)
Number of treatment arms
2 71 (87)
3 6 (7)
4 5 (6)
Randomisation process
Web-based 22 (27)
Telephone-based 11 (13)
Web-based or telephone-based 8 (10)
Sealed envelopes 7 (9)
Otherc 6 (7)
Unclear 28 (34)
Randomisation method
Unstratified permuted blocks 6 (7)
Stratified permuted blocks 41 (50)
Minimisation 5 (6)
Otherd 6 (7)
Uncleare 24 (29)
Repeat randomisations allowed
No 12 (15)
Unclear 70 (85)
Protocol publicly available 63 (77)
aValues are number (percentage) unless otherwise indicated.
bExcludes five trials where the number of centres was not stated.
cIncludes three trials with technology-based randomisation processes
(pager, fax, email) and three trials with physical randomisation processes
(opening next available treatment pack).
dIncludes two trials using biased coin randomisation and four trials using
a combination of stratification and minimisation.
eIncludes 18 trials where randomisation was stratified, but blocking was
not mentioned.
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on the type of error, how often it occurs and how it is
handled during the conduct of the trial and in the anal-
ysis. By far the most commonly reported error found in
this review was ineligible participants inadvertently
being randomised. This is a serious concern, since the
trial treatments under investigation may be inappropri-
ate or harmful for ineligible participants,2 and care
must be taken if they are to be excluded from the anal-
ysis to avoid potential bias.10–12 Unfortunately, such
errors are unavoidable in some scenarios, as partici-
pants may appear to be eligible based on the informa-
tion available at the time of randomisation and only
later be identified as ineligible. Another common but
far less concerning reported error was failure to rando-
mise people who were eligible for the trial and had pro-
vided consent to participate. These missed
opportunities will lead to increased time required to
meet recruitment targets and could impact on the gen-
eralisability of the trial results but will not bias treat-
ment group comparisons. Contrary to our
expectations, no trial reported randomising the same
participant twice in error in the trial publication,
although two occurrences were identified through con-
tacting authors and we have experienced this error in
our own trials. These repeat randomisations introduce
the possibility of choosing the preferred randomised
treatment for the participant, which could introduce
bias. While few instances of using incorrect baseline
information to perform the randomisation were
reported, the implications of these errors can be sub-
stantial, particularly for dynamic allocation methods
such as minimisation, as even one error will alter the
probability of receiving the treatment for future partici-
pants.1 Given that balancing variables should be con-
trolled for in the analysis,13 these errors raise the
question of whether an adjusted analysis should be per-
formed using the correct baseline variables or the incor-
rect versions used to perform the randomisation, and
this issue is being investigated separately.
Our review highlights several inadequacies in current
reporting practices relating to recruitment, randomisa-
tion and treatment errors. First, many trial reports
failed to clearly describe the methods used to generate
the randomisation sequence and perform the randomi-
sation, making it difficult to understand the types of
randomisation errors that were possible. This finding is
surprising, since it is recommended that both the
‘sequence generation’ and ‘allocation concealment
mechanism’ be fully described in the current
CONSORT statement.3,4 The lack of detail on rando-
misation methods may be explained by the common
practice of making trial protocols publicly available
Table 2. Reporting of recruitment, randomisation and treatment errors in trial publications.
Error Number (%) of
trials reporting
error (n = 82)
Median (range)
total number of
errors
reporteda
Median (range) number of
errors reported per 10,000
participants randomiseda
Ineligible participant randomised 23 (28) 12 (1–80) 91 (9–934)
Participant randomised using incorrect baseline
information
2 (2)b 6 (4–8) 164 (78–250)
Participant incorrectly randomised multiple
times
0 (0) N/A N/A
Participant received incorrect treatmentc 4 (5) 6 (2–8) 41 (21–41)
Other errors 9 (11) 2 (1–176) 28 (2–877)
Eligible participant not randomised due to
randomisation system being unavailable
1 (1) 7 28
Participant received study product before
being randomised
1 (1) 2 2
Participant received study product but was
never randomised
1 (1) 2 9
Eligible person consented but was not
randomised
1 (1) 176 877
Participant randomised following improper
consent procedures
2 (2) 1 (1–1) 30 (28–32)
Randomised participant included in subgroup
undergoing further randomisation without
meeting eligibility criteria for subgroup
1 (1) 11 27
Participant randomised in error without
further details provided regarding the nature
of the error
2 (2) 6 (2–10) 40 (28–51)
aCalculated across trials where error was reported. Range not presented for errors reported in only one trial.
bBoth trials used stratified permuted blocks.
cExcludes cases where participant received incorrect treatment due to a deliberate departure from the assigned treatment or where the reason
was unclear.
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combined with the strict word limits applied by the
journals. Second, few trials indicated whether repeat
participation was permitted in the inclusion/exclusion
criteria, and thus it was often unclear whether a repeat
randomisation would be considered an error or not.
Third, recruitment, randomisation and treatment errors
were often poorly reported, making it difficult to iden-
tify how many errors had occurred (if any). For
instance, many trials reported that some participants
failed to receive the allocated treatment, as recom-
mended in the CONSORT flow diagram,3,4 but insuffi-
cient detail was provided to determine whether any
cases resulted from an error. Fourth, some trials did not
report all recruitment, randomisation and treatment
errors that occurred in the trial publication and hence
under-reporting is a concern. Finally, it was often chal-
lenging to determine how any errors that were reported
were handled during the conduct of the trial and in the
analysis. This is problematic, given the potential for bias
to be introduced into treatment effect estimates if cer-
tain errors are handled incorrectly. Reporting standards
are needed to address these inadequacies.
Reporting recommendations
We make several recommendations for reporting
recruitment, randomisation and treatment errors in trial
publications that could be incorporated into formal
reporting standards in future. Our recommendations
are based on the findings of this review and the collec-
tive trial experience of the authorship team that has
been obtained from serving as trial statisticians, investi-
gators and members of independent data monitoring
committees involved mainly with publicly funded ran-
domised trials in health-related disciplines. Consistent
with the CONSORT statement,3,4 our recommenda-
tions focus on promoting transparency in reporting,
rather than how errors should be handled. Specifically,
we recommend the following:
1. Fully describe the method of randomisation by fol-
lowing the reporting recommendations in the
CONSORT statement.3,4
2. Indicate whether repeat participation in the trial
was permitted in the inclusion/exclusion criteria.
3. Report the number and type of recruitment, rando-
misation and treatment errors that occurred during
the trial by treatment group (where applicable), or
state that no errors were identified.
4. Provide details on how the errors were handled
during the conduct of the trial and in the analysis.
The best location in a trial manuscript to report on
recruitment, randomisation and treatment errors is
open to debate. For trials with few errors that are easily
described, these could be included in the participant
flow diagram with additional details provided in foot-
notes. For trials where a range of errors occurred, these
may best be reported in a table. Given the strict word
limits applied by many journals and the increasing use
of online supplements, we suggest including such a table
in a supplementary results file. An example of such a
table is given for a hypothetical trial in Table 3. While
the approaches used to handle the errors during the
conduct of the trial and in the analysis in this hypotheti-
cal trial were chosen to minimise the potential for bias
to be introduced into the treatment group comparisons,
alternative approaches may also be appropriate.1,2
Strengths and limitations
A key strength of this review is that to our knowledge,
it provides the first specific assessment of the prevalence
of recruitment, randomisation and treatment errors
and how they are reported in trial publications. By con-
tacting a random sample of the corresponding authors,
we also provide the first formal evidence of under-
reporting of these errors in trial publications. A limita-
tion is that we did not review additional trial resources
Table 3. Example report of recruitment, randomisation and treatment errors for hypothetical trial.
Error Number of participants affected How error was handled
Ineligible
participant
randomised
6 (4 intervention and 2 control) Treatment was ceased when the ineligibility was
discovered. Outcome data were collected and participants
were included in the intention-to-treat analysis.
Participant
randomised in
incorrect stratum
4 (2 intervention and 2 control) Participants were included in the intention-to-treat
analysis. In the analysis adjusting for the stratification
variables, participants were included in the correct
stratum.
Participant
incorrectly
randomised
multiple times
1 (0 intervention and 1 control) Participant was treated and analysed according to the first
randomisation. The second randomisation was excluded
from the analysis and the corresponding treatment was
not reissued.
Participant
received incorrect
treatment
2 (2 intervention and 0 control) Participants remained on the incorrect treatment for the
duration of the trial. Participants were included in their
randomised group in the intention-to-treat analysis and in
their treated group in the safety analysis.
Yelland et al. 7
such as trial registrations, protocols or other publica-
tions reporting trial results, both for feasibility and
since many readers would only access the main trial
publication. Review of such additional documents may
have provided further details on the randomisation
methods, inclusion/exclusion criteria and any errors
that occurred. A further limitation is that our assess-
ment of the prevalence of errors and current reporting
practices was based on 82 individually randomised,
phase III RCTs published in leading medical journals,
which are unlikely to be representative of all published
RCTs. Likewise, our evidence of under-reporting of
errors was based on responses received from authors of
only a small sample of trials. Although the contacted
trials were chosen at random and should therefore be
representative of all trials included in the review, a
larger study would provide a more accurate estimate of
under-reporting rates.
Conclusion
Recruitment, randomisation and treatment errors are
an important and common problem that has largely
been overlooked in the clinical trials literature.
Researchers should be aware of the possibility of these
errors when designing their trials and give careful con-
sideration to how these errors can be minimised and
how they should be handled during the conduct of the
trial, in the analysis and at the reporting stage. Our
review indicates that reporting of recruitment, rando-
misation and treatment errors is currently inadequate
in individually randomised, phase III RCTs published
in leading medical journals and reporting standards are
needed. Our recommendations for reporting these
errors could be incorporated in a future update of the
CONSORT statement to encourage better planning for
and clearer and more complete reporting of these errors
in reports of clinical trial results.
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